Enodia Therapeutics, a French biotech company, is advancing first-in-class treatment for cancer, inflammatory diseases, and viral infections by targeting the translocon, a key gateway for protein secretion in the cell.
Harnessing a cutting-edge AI-driven approach, we are developing selective small molecule inhibitors that block secretion and promote the degradation of pathological proteins at their source.
Emerging from the Institut Pasteur and nurtured by Argobio, Enodia is built on breakthrough science with a singular mission: unveiling the translocon to unlock innovative therapies.
Company Details
- Founded
- -
- Address
- Paris, 75007, Fr
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://home.enodiatx.com/
- Keywords
- Pfizer.
- HQ
- Paris
Enodia Therapeutics Questions
Enodia Therapeutics's website is https://home.enodiatx.com/
Enodia Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/enodiatx
Enodia Therapeutics's industry is
Biotechnology Research
Enodia Therapeutics's top competitors are
Argobio Studio,
Biolabs,
Inverna Therapeutics,
Adverum Biotechnologies,
Biolabs France,
Pfizer,
Center For Microbiome Innovation,
Elkedonia,
Institut Pasteur,
Roche.
Enodia Therapeutics's categories are Biotechnology Research
Enodia Therapeutics's founding year is 2025
